---
title: "Takeda Pharmaceutical Company: Q1 FY2026 delivered robust core revenue growth, driven by new launches and disciplined investment"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294315248.md"
description: "Q1 FY2026 core revenue grew 10.2% YoY (flat at CER), with strong performance from new launches and core brands offsetting mature portfolio declines. Investments in transformative medicines and R&D continue, with full-year guidance reaffirmed and a focus on deleveraging and dividend growth.Original document: Takeda Pharmaceutical Co. Ltd. [4502] Slides Release — Jul. 30 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-07-30T06:51:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294315248.md)
  - [en](https://longbridge.com/en/news/294315248.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294315248.md)
---

# Takeda Pharmaceutical Company: Q1 FY2026 delivered robust core revenue growth, driven by new launches and disciplined investment

Q1 FY2026 core revenue grew 10.2% YoY (flat at CER), with strong performance from new launches and core brands offsetting mature portfolio declines. Investments in transformative medicines and R&D continue, with full-year guidance reaffirmed and a focus on deleveraging and dividend growth.

Original document: Takeda Pharmaceutical Co. Ltd. \[4502\] Slides Release — Jul. 30 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [TAK.US](https://longbridge.com/en/quote/TAK.US.md)
- [4502.JP](https://longbridge.com/en/quote/4502.JP.md)

## Related News & Research

- [Takeda Pharmaceutical (NYSE:TAK) General Counsel Natalie Anne Marie Furney Sells 30,868 Shares of Stock](https://longbridge.com/en/news/295785108.md)
- [Takeda Pharmaceutical Insiders Sold Shares Worth Over $3.5M](https://longbridge.com/en/news/295731657.md)
- [Vinod Khosla Says AI Is Creating a ‘Hyperabundance’ of New Drugs, but Testing Is Still ‘18th-Century’](https://longbridge.com/en/news/295770785.md)
- [TRAW: Net loss increased, cash is insufficient for 12 months, and Nasdaq delisting risk remains high](https://longbridge.com/en/news/295974913.md)
- [Weekly Recap: Zasocitinib PASI-100 success and Q1 revenue +10.2%](https://longbridge.com/en/news/294743602.md)